HomeCompareOTCM vs PFE

OTCM vs PFE: Dividend Comparison 2026

OTCM yields 4.84% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OTCM wins by $2759.37M in total portfolio value
10 years
OTCM
OTCM
● Live price
4.84%
Share price
$53.53
Annual div
$2.59
5Y div CAGR
96.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2759.42M
Annual income
$2,637,021,193.96
Full OTCM calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — OTCM vs PFE

📍 OTCM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOTCMPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OTCM + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OTCM pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTCM
Annual income on $10K today (after 15% tax)
$411.26/yr
After 10yr DRIP, annual income (after tax)
$2,241,468,014.87/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, OTCM beats the other by $2,241,445,694.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTCM + PFE for your $10,000?

OTCM: 50%PFE: 50%
100% PFE50/50100% OTCM
Portfolio after 10yr
$1379.74M
Annual income
$1,318,523,726.34/yr
Blended yield
95.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OTCM
No analyst data
Altman Z
8.9
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTCM buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOTCMPFE
Forward yield4.84%6.13%
Annual dividend / share$2.59$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR96.9%13.2%
Portfolio after 10y$2759.42M$49.6K
Annual income after 10y$2,637,021,193.96$26,258.71
Total dividends collected$2750.72M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OTCM vs PFE ($10,000, DRIP)

YearOTCM PortfolioOTCM Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,653$952.68$9,153$693.39+$2.5KOTCM
2$14,511$2,042.85$8,593$849.25+$5.9KOTCM
3$20,208$4,681.40$8,336$1,066.78+$11.9KOTCM
4$33,620$11,996.82$8,437$1,384.80+$25.2KOTCM
5$72,701$36,727.49$9,013$1,875.40+$63.7KOTCM
6$223,939$146,149.22$10,306$2,680.72+$213.6KOTCM
7$1,068,033$828,418.01$12,820$4,101.38+$1.06MOTCM
8$8,413,330$7,270,534.76$17,673$6,826.70+$8.40MOTCM
9$114,395,236$105,392,972.85$27,543$12,591.86+$114.37MOTCM
10$2,759,424,096$2,637,021,193.96$49,560$26,258.71+$2759.37MOTCM

OTCM vs PFE: Complete Analysis 2026

OTCMStock

OTC Markets Group Inc. engages in the financial market business in the United States and internationally. It offers OTC Link Alternative Trading System, an interdealer quotation and trade messaging system; OTC Dealer, a real-time, front-end application that provides consolidated quotation, trading, and information system to attract and access market liquidity; OTC FIX, which uses the industry standard FIX protocol for quote submission, trading, and routing of execution reports; and OTC Link Electronic Communication Networks (ECN) and OTC Link National Quotation Bureau (NQB) that acts as the executing party on an agency basis in relation to transactions executed on platforms. The company also provides OTC Markets Real-Time Data products that provides quote, trade, and reference data for OTC Link ATS; OTC Markets Pricing and Reference Data products for detailed view into the securities and issuers within the OTC market; and compliance data products. In addition, it offers OTC Disclosure & News Service for publishing and distributing data, news, and financials; Real-Time Level 2 Quote Display, a service that companies sponsor to provide their investors with access to real-time level 2 quotes on otcmarkets.com and the issuer's Website; Blue Sky Monitoring Service for analysis, review, and guidance about a company's compliance with the United States securities laws; and Virtual Investor Conferences, which allows issuers to communicate and engages with investors, as well as operates the OTCQX Best Market, OTCQB Venture Market, and Pink Open Market. Further, it offers software, and risk and performance analytics tools for the banking and finance industries; online capital raising solutions; and OTCIQ, an investor relations portal. The company was formerly known as Pink OTC Markets Inc. and changed its name to OTC Markets Group Inc. in January 2011. OTC Markets Group Inc. was founded in 1904 and is headquartered in New York, New York.

Full OTCM Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OTCM vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTCM vs SCHDOTCM vs JEPIOTCM vs OOTCM vs KOOTCM vs MAINOTCM vs JNJOTCM vs MRKOTCM vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.